2023年12月1日-3日，欧洲肿瘤内科学会亚洲年会（ESMO ASIA）于新加坡举办。ESMO ASIA是亚太地区讨论肿瘤学领域重磅突破的领先平台，届时将公布多项全球及亚太地区的最新科研和临床进展。在肺癌领域又有哪些重磅研究成果发布呢？让我们先睹为快！

ALK突变NSCLC

ALINA研究亚组分析：辅助阿来替尼对比铂类化疗(CT)在亚洲早期ALK+ NSCLC可切除患者中的疗效和安全性

LBA1 - Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK+ non-small cell lung cancer (NSCLC): A sub analysis of ALINA

时间：12月02日11:15 AM - 11:25 AM

讲者：Jin Seok Ahn (Seoul, KR)

EGFR突变NSCLC

EXCLAIM-2：莫博赛替尼对比铂类化疗一线治疗EGFR ex20ins+局部晚期/转移性NSCLC患者的III期试验

507O - EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC

时间：12月02日10:45 AM - 10:55 AM

讲者：Pasi A. Jänne (Boston, US)

PAPILLON亚组分析：Amivantamab联合化疗对比单独化疗一线治疗亚洲EGFR ex20ins+晚期或转移性NSCLC

513MO - Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis

时间：12月03日09:05 AM - 09:10 AM

讲者：Byoung Chul Cho (Seoul, KR)

MARIPOSA 亚组分析：Amivantamab联合 lazertinib对比奥希替尼一线治疗亚洲EGFR突变晚期NSCLC患者

LBA10 - Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis

时间：12月01日10:45 AM - 10:55 AM

讲者：Hidetoshi Hayashi (Osaka, JP)

MARIPOSA-2 亚组分析：Amivantamab联合化疗对比化疗治疗接受奥希替尼进展的亚洲EGFR突变晚期NSCLC患者

LBA11 - Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis

时间：12月01日10:55 AM - 11:05 AM

讲者：Victor H. Lee (Hong Kong, HK)

FLAURA2：奥希替尼±化疗一线治疗EGFR突变晚期NSCLC的安全性和CNS结局

512MO - FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCL

讲者：于雁哈尔滨医科大学附属肿瘤医院

时间：2023年12月03日 09:00 AM - 09:05 AM

贝福替尼用于经治EGFR T790M阳性局部晚期或转移性NSCLC患者的最终总生存期结果

LBA9 - Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)

时间：2023年12月03日 09:30 AM - 09:35 AM

讲者：简红上海市胸科医院

RET融合阳性NSCLC

LIBRETTO-431中期分析：塞普替尼对比化疗联合或不联合帕博利珠单抗一线治疗 RET 融合阳性晚期NSCLC患者报告结果

490MO - Patient-reported outcomes of first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive advanced non-small cell lung cancer: Interim analysis of LIBRETTO-431

时间：2023年12月03日 10:00 AM - 10:05 AM

讲者：Koichi Goto (Kashiwa, JP)

ADC

TROPION-Lung01研究：Dato-DXd对比多西他赛在晚期经治NSCLC中的疗效

509MO - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

时间：12月02日 09:05 AM - 09:10 AM

讲者：Myung-Ju Ahn (Seoul, KR)

DESTINY–Lung02亚组分析：T-DXd在亚洲HER2突变转移性NSCLC患者中的疗效

510MO - Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02)

时间：12月02日 09:10 AM - 09:15 AM

讲者：Yasushi Goto (Chuo-ku, JP)

telisotuzumab vedotin (Teliso-V) 联合奥希替尼治疗EGFR突变、c-Met过表达的晚期NSCLC：最终疗效和安全性结果更新

515MO - Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates

时间：12月03日09:35 AM - 09:40 AM

讲者：Hidehito Horinouchi (Chuo-ku, JP)

TROPION-Lung05研究：Dato-DXd用于既往经治的具有可靶向基因组改变 (AGAs) 的NSCLC

518MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

时间：12月03日10:05 AM - 10:10 AM

讲者：Satoru Kitazono (Koto-ku, JP)

创新药物

IBI351（GFH925，一种选择性KRASG12C抑制剂）单药治疗晚期NSCLC患者的疗效和安全性：II期注册研究的初步结果

LBA12 - Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II study

时间：12月01日 11:25 AM - 11:35 AM

讲者：Jiaxin Lin（广州中国）

SHR-1701（一种靶向PD-L1和TGF-β的双功能融合蛋白）在晚期NSCLC患者中的I期研究结果

511MO-A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced non-small cell lung cancer (NSCLC)

时间：12月02日 09:35 AM - 09:40 AM

讲者：冯继锋江苏省肿瘤医院

MCLA-129（一种抗 EGFR/c-MET 双特异性抗体）联合奥希替尼作为一线治疗或奥希替尼进展后的NSCLC治疗方案

516MO - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)

时间：12月03日09:40 AM - 09:45 AM

讲者：Mariana Brandão (Anderlecht, BE)

小细胞肺癌

II 期 DeLLphi-301 研究初步分析：Tarlatamab 用于既往经治的小细胞肺癌 (SCLC) 患者

508MO - Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study

时间：12月02日09:00 AM - 09:05 AM

讲者：Myung-Ju Ahn (Seoul, KR)

1080-1920-宣传海报-定.png